Rallybio raises $145m in Series B round for developing rare disease drug candidates

This article was originally published here

According to Rallybio, new investors who took part in the funding round included Viking Global Investors, TPG’s The Rise Fund, funds managed by Tekla Capital Management, F-Prime Capital,

The post Rallybio raises $145m in Series B round for developing rare disease drug candidates appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply